← Back to headlines
Biotechnology Faces Patent Cliff, Sparking Asset Acquisition Race
The biotechnology sector is approaching a "patent cliff" between 2025 and 2030, with drugs generating over $200 billion in annual revenue set to lose patent protection. Global corporations are scrambling to fill pipeline gaps, particularly targeting oncology, obesity, RNA, and gene therapies.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
